C. Chambers

Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months

Background  Rational healthcare decision‐making based on clinical and economic evidence is essential to provide the best possible care for patients with atopic dermatitis (AD).

Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature

AIMS Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes mellitus. A systematic literature review was conducted to provide an overview of published literature in the last 10-years on the epidemiology, humanistic burden and economic burden of PDPN in Europe. METHODS A search was performed according to pre-defined strategy and review criteria in Embase, Pubmed, and conference proceedings databases from 2003 till December 2012. In total, 30 publications written in English covering the relevant patient population and topics of interest. RESULTS European prevalence ranges from 6% to 34% in diabetes mellitus patients. PDPN has a significant humanistic and economic impact. Patients are limited in their general functioning and their ability to sleep and often experience anxiety and depression. Not surprisingly, PDPN is associated with reduced Health-Related-Quality-of-Life (HRQoL). PDPN patients incur high health care costs due to hospitalizations and outpatient visits. In addition, the painful symptoms cause impaired work productivity. Studies suggest both humanistic and economic burden increase with higher pain severity. CONCLUSIONS The burden from PDPN appears to be higher with increasing pain severity. More severe pain leads to a higher impairment in daily functioning, sleep and HRQoL. Higher pain intensity also leads to increasing healthcare costs and work productivity losses.

Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids.

Background  The purpose of this study was to measure change in quality of life (QoL) and estimate health‐related utility in adults with moderate and severe atopic dermatitis (AD) following the use of either tacrolimus ointment or topical corticosteroids.

Health-related utility among adults with atopic dermatitis treated with 0·1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic® CONTROL study

Background  Long‐term maintenance treatment with 0·1% tacrolimus ointment for the prevention of flares has been demonstrated to be well tolerated and effective in adults for the treatment of atopic dermatitis (AD) but its impact on health‐related utility has not been reported.

Cost Effectiveness Of Solifenacin Compared With Oral Antimuscarinic Agents For The Treatment Of Patients With Overactive Bladder (Oab) In The Uk

Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. ...

PSS15 CHANGES IN HEALTH RELATED UTILITY AMONG ADULTS WITH ATOPIC DERMATITIS TREATED WITH TACROLIMUS OINTMENT COMPARED TO A STANDARD CORTICOSTEROID REGIMEN

OBJECTIVES: Long-term treatment with 0.1% tacrolimus ointment (TO) has been demonstrated as well-tolerated and effective for the treatment of atopic dermatitis (AD) but its impact on utility has not been reported. The purpose of this study was to estimate utility changes associated with TO versus a standard corticosteroid regimen (CR) in the treatment of moderate-to-severe AD in adults. METHODS: Data were analysed from a double-blind RCT. Patients were treated with either TO applied twice-daily for six months to the head, neck, trunk and extremities, or alternatively 0.1% hydrocortisone butyrate ointment administered to the trunk and extremities and 1% hydrocortisone acetate ointment applied to the head and neck. Health-related utility (EQ5Dindex) was estimated by Monte Carlo simulation from SF12 responses collected during the clinical trial by applying a published mapping algorithm. RESULTS: Data were available for 972 patients (intention-to-treat), 46% of whom were male with a mean age of 32 years (SD 12). At baseline the mean EQ5Dindex was similar between both arms (0.721 vs. 0.730; p = 0.461, for CR vs. TO, respectively). After 28 days the mean EQ5Dindex improved in both treatment arms (0.820 vs. 0.849; p = 0.004, respectively). The incremental EQ5Dindex between the treatment arms increased as the trial progressed. At 6-months subjects treated with TO had signifi cantly higher utility than CR-treated subjects (0.789 vs. 0.831; p = 0.001; respectively). CONCLUSIONS: Patients with AD had considerable decrement in health-related utility at baseline. Treatment with 0.1% tacrolimus ointment was associated with a consistently improved, clinically-signifi cant, incremental increase in health-related utility compared to the corticosteroid regimen, increasing over a six month period.